The nursery is always quietest just before dawn. In the soft gray light, a mother watches her three-month-old son sleep. He is beautiful. His skin is warm, his breathing steady. But over the last two weeks, a quiet terror has settled into the corners of the room. When he lies on his back, his legs do not kick with the frantic, joyful energy they did a month ago. When she places her finger in his tiny palm, his grip is soft. Floppy.
She tells herself she is imagining things. She tells herself that babies develop at their own pace. Don't miss our recent article on this related article.
But a pediatrician like me has seen this quietness before. It is the signature of a thief.
For decades, spinal muscular atrophy, or SMA, has behaved like an invisible burglar in the nursery. It is a rare genetic condition that slowly, systematically dismantles a baby’s physical abilities. In the UK, about four babies are born with this condition every single month. Sixty percent of them have Type 1, the most aggressive variation. Without intervention, these babies eventually lose the ability to hold up their heads, to swallow, and, ultimately, to breathe. If you want more about the history here, Healthline provides an informative breakdown.
Historically, by the time a parent notices the subtle floppiness, the thief has already made off with the prize.
The Blueprint and the Broken Switch
To understand SMA, we have to look at how our bodies talk to our muscles.
Consider a simple analogy. Your brain is a bustling central station, and your muscles are distant towns. The tracks connecting them are motor neurons—specialized nerve cells in the spinal cord. To keep these tracks maintained, the body needs a specific protein. This protein is manufactured by a gene called SMN1.
In children born with SMA, both copies of this gene are missing or damaged.
Without that genetic instruction manual, the body cannot produce the vital protein. The tracks begin to decay. The brain shouts commands to the legs, the arms, and the diaphragm, but the signals travel down broken lines. They vanish into the dark.
For years, a diagnosis of SMA Type 1 was a slow-motion tragedy. We could only offer comfort, supportive ventilation, and wheelchairs. Then came a revolution. Scientists developed remarkable, highly sophisticated therapies capable of patching the genetic blueprint or boosting alternative genes. Today, the NHS offers three highly effective treatments, including a one-time gene therapy that delivers a functional copy of the missing gene directly to the cells.
But there is a catch. A massive, heartbreaking catch.
These treatments cannot rebuild what is already lost. Motor neurons are fragile, irreplaceable assets. Once they wither and die, they are gone forever. If we wait until a baby is showing symptoms—until their legs are still and their cry is weak—we are fighting a rearguard action. We are trying to save a house that has already partially burned down.
The goal, therefore, is to find these children before the first spark catches.
A Postcode Lottery of Survival
For a long time, whether a child survived SMA depended entirely on where their parents happened to live.
Take a hypothetical pair of families living just hours apart. Let us call them the Taylors and the Patels, composite families representing the very real geographic divides we have navigated for years.
If the Taylors had their baby in Edinburgh in the spring of 2026, their child was screened for SMA at birth. Scotland began national newborn screening for the condition in March of that year. Within days of birth, a simple test flag would alert doctors, treatment would begin, and the child could grow up walking, jumping, and running.
Now consider the Patels, living just across the border in England. If their baby was born in the summer of 2026, their hospital did not yet offer the test. They had to wait. They had to watch for the first signs of muscle weakness. By the time the diagnosis arrived, irreversible damage had occurred. Same disease. Same country. Two entirely different lives.
This regional disparity is what we in the medical community call a postcode lottery. It is an ethical failure of geography.
Fortunately, that map is about to be rewritten.
Following years of fierce advocacy by charities like SMA UK, clinical researchers, and public figures like Jesy Nelson—who championed the cause after witnessing the devastating effects of delayed diagnosis firsthand—change is finally arriving.
The Department of Health and Social Care, led by Health Secretary James Murray and bolstered by a £4.1 million national evaluation, has accelerated the timeline. Starting in October 2026, a massive, staggered rollout will begin, covering 72% of newborn screening laboratories in England.
But the true victory lies in what happens next. By October 2027, the remaining six newborn screening laboratories in England will come online.
At that moment, the postcode lottery ends. Every single baby born in England will be screened for SMA, regardless of where their crib is located.
Five Drops on a Card
The weapon we are using to defeat this disease is astonishingly low-tech in its delivery.
It is called the heel-prick test.
If you have ever had a baby, you know the ritual. Around the fifth day of life, a midwife visits the home or enters the hospital room. They gently warm the baby’s heel, hold a tiny lancet, and make a quick, clean prick. The baby lets out a brief, indignant cry.
The midwife then presses the heel against a piece of absorbent card, filling five pre-printed circles with deep red blood.
Currently, this card is used to screen for nine rare but serious conditions, such as cystic fibrosis and sickle cell disease. Adding SMA to this established panel is a logistical feat, but a clinically simple one. Those five drops of blood are sent to a laboratory where scientists look directly at the DNA.
They are not looking for symptoms. They are looking for the missing SMN1 gene.
If the gene is absent, the laboratory alerts a specialist center immediately. Before the parents have noticed a single missed milestone—before the child has even had their first smile—the medical team is preparing the treatment.
I have spoken with clinicians who have treated babies identified through early screening pilots. They describe it as nothing short of a miracle. Children who genetically have the most severe form of SMA are running around playgrounds. They are climbing trees. They are living lives completely indistinguishable from their peers.
The Weight of the Wait
It is easy to look at policy decisions and laboratory rollouts as triumphs of bureaucracy. But behind the announcements, the funding packages, and the parliamentary debates are human beings who fought through unimaginable grief to make this happen.
I remember a mother I worked with years ago. Her daughter had been diagnosed with SMA Type 1 at five months old. I had to sit in a small, windowless consultation room and explain that while we had treatments, they could not restore the strength her baby had already lost.
I watched this mother's face collapse as she realized that the future she had imagined—ballet classes, walks in the park, holding hands on the way to school—was evaporating. She looked at me through her tears and asked a question that has haunted me ever since.
"Why didn't they check her when she was born?"
For years, I did not have a good answer. We had the technology. We had the treatments. We just did not have the system.
The rollout starting in October 2026, culminating in full national coverage by October 2027, is the answer to her question. It is a monument to every parent who had to bury a child, every advocate who refused to accept "no" from a committee, and every researcher who spent late nights under the glow of fluorescent laboratory lights.
The transition will not happen overnight. The staggered approach is a practical necessity, allowing the NHS to scale up its laboratory capacity and ensure that when a positive result is found, a clinical team is ready to act instantly. It is a massive undertaking, but the destination is clear.
Soon, the quietness of a nursery will no longer be a source of fear.
A mother will watch her three-month-old sleep in the gray morning light. She will see his legs kick, strong and restless against the blanket. She will smile, entirely unaware of the silent thief that once stalked the cradle, and entirely unaware that five drops of blood on a cardboard strip saved her son's life before she even brought him home.
